GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Mar 21, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Mar 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on March 21, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- 31¼ pence (dollar_amount) — Nominal value of ordinary shares
FAQ
What was the date of the share purchase announcement?
The announcement was made on March 21, 2025.
Who acted as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as the corporate stockbroker.
What type of shares did GSK purchase?
GSK purchased its own ordinary shares of 31¼ pence each.
Does this filing specify the number of shares purchased?
No, the filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not provide the specific quantity in the excerpt.
Is GSK required to file annual reports on Form 20-F or 40-F?
Yes, GSK indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 21, 2025 regarding GSK plc (GLAXF).